Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC2 | O75106 | 2/20 | 0.32 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9050598 | 1.00 | AOC2 (0.32) | AOC2MAOAPTGS1PDE4ALMNA | |
| SCHEMBL2572863 | 0.88 | PTGS1 (0.32) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL2573293 | 0.88 | APP (0.34) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL21216764 | 0.80 | AOC2 (0.32) | AOC2MAOA | |
| SCHEMBL23160212 | 0.79 | INPP5A (0.44) | AOC2MAOA | |
| SCHEMBL1647665 | 0.79 | INPP5A (0.44) | AOC2MAOA | |
| SCHEMBL23012533 | 0.79 | INPP5A (0.44) | AOC2MAOA | |
| SCHEMBL2570161 | 0.78 | APP (0.38) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL6962289 | 0.78 | INPP5A (0.42) | AOC2MAOA | |
| SCHEMBL29086645 | 0.76 | AOC2 (0.32) | AOC2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022266426-A1 | 6-(HETEROCYCLOALKYL-OXY)-QUINAZOLINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |